Global Kinetics to present at philanthropic forum
Melbourne-based medical technology company Global Kinetics Corporation will present details of its Parkinson’s Kinetograph (PKG) at the Cavendish Global Health Impact Forum next month.
The company has been selected to present at the philanthropic forum, which will be held in New York from 5-7 May.
The company’s PKG technology is designed to record data about the presence and severity of Parkinson’s symptoms bradykinesia and dyskinesia, to allow neurologists to objectively analyse a patient’s movement disorder symptoms.
Movement data is collected via a wrist-worn device, which also has the capability to remind Parkinson’s patients to take their medication on schedule.
The PKG is approved in Australia and Europe, and is in use in nine countries worldwide.
Global Kinetics CEO Andrew Maxwell said presenting at the forum will give the company an “opportunity to interact with many of the world’s leading scientific minds, thought leaders and generous philanthropic individuals and families who are dedicated to the common cause of improving the health and lives of people around the world.”
Cavendish Global is an alliance of over 150 family offices and philanthropic foundations with combined assets of over $190 billion.
Global Kinetics Corporation was founded in 2007 to commercialise technology developed by researchers from the Florey Institute of Neuroscience & Mental Health.
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
